VRTX — Vertex Pharmaceuticals Incorporated stock price and chart

Share this page

VRTX

$503.50-0.24%

as of close, Oct 5, 2026

☾ AH $503.50 -0.24%

Vertex Pharmaceuticals IncorporatedStock · HealthcareNasdaq-100 0.5%Nasdaq Composite 0.2%S&P 500 Equal Weight 0.2%S&P 500 0.2%Russell 1000 0.2%Russell 3000 0.2%US Stock Market 0.2%MSCI World 0.1%MSCI ACWI 0.1%

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

100.0150.0200.0250.0300.0350.0400.0450.0500.0550.0020.0M$503.50

2026-10-05

Price$503.50

MA20$485.02

MA50$454.92

Vol4.2M

What would $1,000 invested in VRTX be worth today? →

VRTX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $503.50
YTD price return: +11.06%
YTD total return: +11.06%
Next earnings: Nov 2, 2026
Market cap: 127.6B2016-12 18.3B2026-10 127.6B+598.4% over the window
Enterprise value: 121.8B
Shares outstanding: 253.5M2016-06 247.8M2026-06 253.5M+2.3% over the window
52W low: $400.74
52W high: $560.25
From 52W high: -10.13%
From 52W low: +25.64%
52W range: 64%
Beta: 0.30

Volume

Rel volume: 0.92×
30D volume: 989.7K
30D $ vol: 521.2M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3MNo open-market insider purchase or sale with a transaction date in the last 91 days, as filed on Form 4.: none
Insider net 1Y0 insider-days of buying (no priced lot) and 51 of selling ($87.5M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$87.5M

Form 4 transactions by trade date, as filed; latest on file 2026-07-02.

Fundamentals

Sales (ttm): 12.6B2016-06 1.6B2026-06 12.6B+708.2% over the window
Sales/share: $49.662016-06 $6.292026-06 $49.66+690.1% over the window
EPS (ttm): $17.192016-06 -$1.132026-06 $17.19-1620.4% over the window
FCF (ttm): 3.8B2016-06 -56.4M2026-06 3.8B-6827.9% over the window
FCF/share: $14.982016-06 -$0.232026-06 $14.98-6677.1% over the window
Book value/share: $79.892016-06 $3.962026-06 $79.89+1917.0% over the window
Net margin: 35.00%2016-06 -17.7%2026-06 35.0%-298.2% over the window
ROE: 21.76%2016-06 -28.0%2026-06 21.8%-177.6% over the window
ROA: 16.06%2016-06 -10.8%2026-06 16.1%-248.9% over the window
Current ratio: 3.192016-06 2.332026-06 3.19+36.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +10.24%2025-06-30 → 2026-06-3011.4B → 12.6B (+10.2% total)+9.81%2023-06-30 → 2026-06-309.5B → 12.6B (+32.4% total)+13.50%2021-06-30 → 2026-06-306.7B → 12.6B (+88.3% total)+23.24%2016-06-30 → 2026-06-301.6B → 12.6B (+708.2% total)
Net income: +21.12%2025-06-30 → 2026-06-303.6B → 4.4B (+21.1% total)+9.39%2023-06-30 → 2026-06-303.4B → 4.4B (+30.9% total)+17.21%2021-06-30 → 2026-06-302B → 4.4B (+121.2% total)n/a
FCF: +8.48%2025-06-30 → 2026-06-303.5B → 3.8B (+8.5% total)-0.71%2023-06-30 → 2026-06-303.9B → 3.8B (-2.1% total)+16.39%2021-06-30 → 2026-06-301.8B → 3.8B (+113.6% total)n/a
Shares: -1.14%2025-06-30 → 2026-06-30256.4M → 253.5M (-1.1% total)-0.60%2023-06-30 → 2026-06-30258.1M → 253.5M (-1.8% total)-0.46%2021-06-30 → 2026-06-30259.4M → 253.5M (-2.3% total)+0.23%2016-06-30 → 2026-06-30247.8M → 253.5M (+2.3% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +22.47%2025-06-30 → 2026-06-30$14.04 → $17.19 (+22.4% total)+9.93%2023-06-30 → 2026-06-30$12.94 → $17.19 (+32.9% total)+17.79%2021-06-30 → 2026-06-30$7.58 → $17.19 (+126.7% total)n/a
Sales/share: +11.51%2025-06-30 → 2026-06-30$44.54 → $49.66 (+11.5% total)+10.48%2023-06-30 → 2026-06-30$36.83 → $49.66 (+34.8% total)+14.03%2021-06-30 → 2026-06-30$25.76 → $49.66 (+92.8% total)+22.96%2016-06-30 → 2026-06-30$6.29 → $49.66 (+690.1% total)
FCF/share: +9.73%2025-06-30 → 2026-06-30$13.65 → $14.98 (+9.7% total)-0.11%2023-06-30 → 2026-06-30$15.03 → $14.98 (-0.3% total)+16.94%2021-06-30 → 2026-06-30$6.85 → $14.98 (+118.6% total)n/a
Book value/share: +19.27%2025-06-30 → 2026-06-30$66.99 → $79.89 (+19.3% total)+10.05%2023-06-30 → 2026-06-30$59.94 → $79.89 (+33.3% total)+17.65%2021-06-30 → 2026-06-30$35.45 → $79.89 (+125.4% total)+35.05%2016-06-30 → 2026-06-30$3.96 → $79.89 (+1917.0% total)
Price: +25.06%2025-10-06 → 2026-10-05$402.90 → $503.50 (+25.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.34%2023-10-05 → 2026-10-05$355.14 → $503.50 (+41.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+23.26%2021-10-05 → 2026-10-05$177.01 → $503.50 (+184.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+19.27%2016-10-04 → 2026-10-05$86.42 → $503.50 (+482.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +25.06%2025-10-06 → 2026-10-05$402.90 → $503.50 (+25.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+12.34%2023-10-05 → 2026-10-05$355.14 → $503.50 (+41.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+23.26%2021-10-05 → 2026-10-05$177.01 → $503.50 (+184.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+19.27%2016-10-04 → 2026-10-05$86.42 → $503.50 (+482.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 29.3×2016-12 -83.542026-10 28.97-134.7% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 26.7×2016-12 -219.082026-10 26.71-112.2% over the window
Fwd P/E: 25.1×
P/S (ttm)Market cap ÷ TTM revenue.: 10.1×2016-12 11.002026-10 10.14-7.8% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.3×2016-12 17.892026-10 6.30-64.8% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 33.6×2016-12 275.942026-10 33.62-87.8% over the window
EV/EBITDA (fy): 24.4×
EV/Sales (ttm): 9.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.97%2016-09 0.4%2026-06 3.0%+727.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 253.5M ÷ 256.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.14%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.14%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($114.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 1.14%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($2B) ÷ today's market cap ($127.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 1.57%2016-09 0.0%2026-06 1.6%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $2B + TTM dividends $0) ÷ today's market cap ($127.6B). Same caveat as the cash buyback yield.: 1.57%2016-09 0.0%2026-06 1.6%

Vs own 10Y history

P/E: 58th
P/OI: 46th
P/S: 43rd
P/B: 36th
P/FCF: 56th

Bar = where today’s multiple sits in VRTX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-05#

-0.24%

-4.58%

-7.80%

-4.65%

YTD

+11.06%

+24.85%

+184.45%

Recent filings#

Sep 18-K · Directors or officers; compensation
Aug 4Report · Quarterly report, Q2 2026 — revenue $3.33B (+12% y/y), net income $1.10B, EPS $4.31
Aug 3Earnings · Earnings release — EPS $4.20 vs $4.15 est. (+1.2%); revenue $3.33B (+12% y/y) 1.7%
Jul 78-K · Material definitive agreement; Regulation FD disclosure; Other events
Jul 2Insider sale · McKechnie Duncan (EVP, Chief Commercial Officer) sold 1,541 shares for $800K at $519.00 under a 10b5-1 plan

All filings and insider trades →

Financial statements

Open full VRTX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-0.54%	+0.02%
JNJ	Johnson & Johnson	-8.10%	-1.21%
ABBV	AbbVie Inc.	+3.63%	+1.12%
MRK	Merck & Co. Inc.	-7.18%	-3.30%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-4.67%	+1.80%
TMO	Thermo Fisher Scientific Inc.	+10.26%	+3.35%
AMGN	Amgen Inc.	-7.83%	-0.01%
GILD	Gilead Sciences Inc.	-4.22%	-0.08%

VRTX — Vertex Pharmaceuticals Incorporated price, chart and key statistics